RxDoctor Payments Data

Victoria Rose, MD

Family Medicine · Rio Grande, NJNPI 1629338231

Payments from drug & device makers

$574in general payments, 2019–2025

Across 19 payments — averaging $30.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$149
  • Johnson & Johnson$97
  • Novo Nordisk$97
  • Procept Biorobotics Corporation$70
  • Pfizer$37
  • Amgen$33
  • plus $92 from 6 others

What the payments were for

  • Food & beverage$574100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$574 in reported general payments places this provider in the 55th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$117,836
Medicare patients
452
Services billed
1,812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate95$126,150
OzempicSemaglutide83$116,654
JardianceEmpagliflozin83$110,690
EliquisApixaban43$67,597
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$53,106
MounjaroTirzepatide32$33,610
FarxigaDapagliflozin Propanediol27$33,379
XareltoRivaroxaban22$30,608
TradjentaLinagliptin12$17,043
EntrestoSacubitril/Valsartan14$16,719
JanumetSitagliptin Phos/Metformin Hcl11$15,025
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$14,879
MyrbetriqMirabegron14$14,209
TrulicityDulaglutide14$13,283
Breo ElliptaFluticasone/Vilanterol17$10,981

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$15$127,73395 claims
Novo NordiskOzempic$97$116,65483 claims
PfizerEliquis$37$67,59743 claims
GSKTrelegy Ellipta, Breo Ellipta$14$64,08781 claims
Lilly USA, LLCMounjaro, Trulicity$14$46,89346 claims
Johnson & JohnsonXarelto$97$30,60822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Rio Grande

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →